<DOC>
	<DOCNO>NCT00293813</DOCNO>
	<brief_summary>This study structure estimate effect denosumab , compare placebo alendronate , several bone parameter .</brief_summary>
	<brief_title>A Multicenter , Randomized Placebo Controlled Pilot MicroCT Study Estimate Effect Treatment With Denosumab ( AMG 162 ) Alendronate Sodium Postmenopausal Women With Low Bone Mineral Density</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Key Postmenopausal , ambulatory woman 50 70 year old generally good health . Must low bone mineral density meet specific eligibility criterion . Key Subjects must currently receive medication affect bone metabolism underlie condition affect ability take alendronate receive denosumab .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Post Menopausal</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>MicroCT</keyword>
	<keyword>Amgen</keyword>
	<keyword>denosumab</keyword>
	<keyword>Extreme CT</keyword>
	<keyword>XCT</keyword>
	<keyword>Fosamax</keyword>
	<keyword>Alendronate</keyword>
</DOC>